ISSAQUAH, Wash.--(BUSINESS WIRE)--BaroPace Inc. announces its Phase I first-in-human trial of PressurePace TM, its patent-pending pacemaker control algorithm for the treatment of heart failure with ...
A key opinion leader provides insight into key HFpEF treatment strategies. This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, ...
–Treatment with HU6 led to significant reductions in body fat and abdominal visceral fat while preserving skeletal muscle in patients with obesity-related heart failure with preserved ejection ...
Designation underscores the potential for VS-041 to address a significant unmet medical need and potentially improve diagnosis by utilizing a serum biomarker VS-041 is being evaluated in a Phase 1c ...
(RTTNews) - Tenax Therapeutics, Inc. (TENX) announced an expansion of its Phase 3 LEVEL program for TNX-103 or oral levosimendan, a novel treatment for pulmonary hypertension with heart failure with ...
CHICAGO — A new study has shown for the first time that a drug therapy can reduce major heart failure clinical outcomes in patients with heart failure and a preserved ejection fraction (HFpEF) and ...
A novel study co-authored by a heart failure cardiologist demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction ...
Tectonic Therapeutic, Inc. announced positive interim results from its Phase 1b clinical trial of TX45, a long-acting Fc-relaxin fusion protein, which demonstrated significant improvements in left ...
CHAPEL HILL, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback